Rigel Pharmaceuticals Q2 2024 GAAP EPS $(0.06) Beats $(0.31) Estimate, Sales $36.841M Beat $33.419M Estimate
Portfolio Pulse from Benzinga Newsdesk
Rigel Pharmaceuticals (NASDAQ:RIGL) reported Q2 2024 GAAP EPS of $(0.06), significantly beating the analyst estimate of $(0.31). The company also reported sales of $36.841 million, surpassing the $33.419 million estimate and marking a 37.03% increase from the same period last year.
August 06, 2024 | 8:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Rigel Pharmaceuticals reported better-than-expected Q2 2024 results with a GAAP EPS of $(0.06) beating the $(0.31) estimate and sales of $36.841 million surpassing the $33.419 million estimate. This represents a 37.03% increase in sales from the same period last year.
The significant beat on both EPS and sales estimates, along with a substantial year-over-year sales increase, is likely to positively impact RIGL's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100